# CONTACT-03 (NCT04338269)

> A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04338269
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Renal Cell
- Interventions: Atezolizumab; Cabozantinib
- Enrollment: 522
- Primary outcome: Progression Free Survival (PFS) as Assessed by an Independent Review Facility (IRF) (IRF-PFS) According to RECIST v1.1
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 97
- YouTube: 42
- Podcasts: 36

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=contact-03-nct04338269

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04338269", "email": "<work email>"}; the inbox owner confirms by the emailed link.